Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetic Retinopathy

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Patient-Reported Outcomes after Surgery for Proliferative Vitreoretinopathy: Post hoc Analysis of a Randomized Controlled Trial.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026

Same author

Impact of Retinotomy on Retinal Displacement after Macula-Involving Retinal Detachment Repair: Post Hoc Analysis of the PostRD Trial.

Retina (Philadelphia, Pa.)·2025

Same author

Economic evaluation of an adjunctive intraocular and peri-ocular steroid vitreoretinal surgery for open globe trauma: Cost-effectiveness of the ASCOT randomised controlled trial.

PloS one·2024

Same author

Spontaneous suprachoroidal haemorrhage: clinical features, visual outcomes and prognosis factors.

Eye (London, England)·2024

Same author

Scleral sutured aniridia intraocular lens (Morcher<sup>®</sup>): indications and long-term outcomes.

Eye (London, England)·2024

Same author

A randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery for open globe trauma - the ASCOT study.

Health technology assessment (Winchester, England)·2023

Search research articles

Related Experiment Video

Updated: Jul 19, 2026

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

Published on: January 25, 2019

Proliferative vitreoretinopathy: developments in pathogenesis and treatment.

Riaz H Y Asaria¹, David G Charteris

¹Royal Free hospital, London, England; Institute of Ophthalmology, London, England. riaz@ophthalmology.demon.co.uk

Comprehensive Ophthalmology Update

|September 30, 2006

Summary

Proliferative vitreoretinopathy, a complication of retinal detachment, still hinders successful retinal reattachment surgery. Ongoing research aims to improve treatments and reduce its incidence, though surgical skill remains key for management.

More Related Videos

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model

Published on: August 5, 2021

Related Experiment Videos

Last Updated: Jul 19, 2026

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

Published on: January 25, 2019

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model

Published on: August 5, 2021

Area of Science:

Ophthalmology
Retinal Surgery
Wound Healing Biology

Background:

Proliferative vitreoretinopathy (PVP) is a significant complication following retinal detachment, affecting 5-10% of cases.
PVP is the primary cause of surgical failure in retinal reattachment procedures.
Despite advancements, PVP remains a leading cause of persistent visual impairment after retinal detachment surgery.

Purpose of the Study:

To review current understanding of the causes of proliferative vitreoretinopathy.
To evaluate emerging adjuvant treatments aimed at improving retinal reattachment surgery outcomes.
To discuss the current and future strategies for preventing and managing PVP.

Main Methods:

Review of recent scientific literature on proliferative vitreoretinopathy.
Analysis of current and investigational treatment modalities.
Evaluation of preventative strategies and surgical management techniques.

Main Results:

Recent research has elucidated the underlying mechanisms of proliferative vitreoretinopathy.
New adjuvant therapies are under investigation to enhance surgical success rates.
Preventative treatments are currently limited to high-risk populations.

Conclusions:

Improved understanding of PVP pathogenesis is paving the way for novel therapeutic approaches.
Targeted immunosuppression holds promise for reducing PVP incidence.
Effective management of proliferative vitreoretinopathy currently relies heavily on surgical expertise.